COVID‐SAFER: Deprescribing Guidance for Hydroxychloroquine Drug Interactions in Older Adults

BACKGROUND/OBJECTIVES Severe acute respiratory syndrome coronavirus 2 (SARS‐CoV‐2) infection causes high morbidity and mortality in older adults with chronic illnesses. Several trials are currently underway evaluating the antimalarial drug hydroxychloroquine as a potential treatment for acute infection. However, polypharmacy predisposes patients to increased risk of drug‐drug interactions with hydroxychloroquine and may render many in this population ineligible to participate in trials. We aimed to quantify the degree of polypharmacy and burden of potentially inappropriate medications (PIMs) that older hospitalized adults are taking that would interact with hydroxychloroquine. METHODS We reanalyzed data from the cohort of patients 65 years and older enrolled in the MedSafer pilot study. We first identified patients taking medications with potentially harmful drug‐drug interactions with hydroxychloroquine that might exclude them from participation in a typical 2019 coronavirus disease (COVID‐19) therapeutic trial. Next, we identified medications that were flagged by MedSafer as potentially inappropriate and crafted guidance around medication management if contemplating the use of hydroxychloroquine. RESULTS The cohort contained a total of 1,001 unique patients with complete data on their home medications at admission. Of these 1,001 patients, 590 (58.9%) were receiving one or more home medications that could potentially interact with hydroxychloroquine, and of these, 255 (43.2%) were flagged as potentially inappropriate by the MedSafer tool. Common classes of PIMs observed were antipsychotics, cardiac medications, and antidiabetic agents. CONCLUSION The COVID‐19 pandemic highlights the importance of medication optimization and deprescribing PIMs in older adults. By acting now to reduce polypharmacy and use of PIMs, we can better prepare this vulnerable population for inclusion in trials and, if substantiated, pharmacologic treatment or prevention of COVID‐19. J Am Geriatr Soc 68:1636‐1646, 2020.

[1]  M. Steinman,et al.  Optimizing Medication Management During the COVID‐19 Pandemic: An Implementation Guide for Post‐Acute and Long‐Term Care , 2020, Journal of the American Geriatrics Society.

[2]  G. Hripcsak,et al.  Observational Study of Hydroxychloroquine in Hospitalized Patients with Covid-19 , 2020, The New England journal of medicine.

[3]  Reem A Mustafa,et al.  Infectious Diseases Society of America Guidelines on the Treatment and Management of Patients with COVID-19 , 2020, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[4]  André Machado Siqueira,et al.  Effect of High vs Low Doses of Chloroquine Diphosphate as Adjunctive Therapy for Patients Hospitalized With Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Infection: A Randomized Clinical Trial. , 2020, JAMA network open.

[5]  T. Jodlowski,et al.  Pharmacologic Treatments for Coronavirus Disease 2019 (COVID-19): A Review. , 2020, JAMA.

[6]  Erwan L'Her,et al.  Compassionate Use of Remdesivir for Patients with Severe Covid-19 , 2020, The New England journal of medicine.

[7]  D. Roden,et al.  Considerations for drug interactions on QTc interval in exploratory COVID-19 treatment , 2020, Journal of the American College of Cardiology.

[8]  D. Roden,et al.  Considerations for Drug Interactions on QTc in Exploratory COVID-19 (Coronavirus Disease 2019) Treatment. , 2020, Circulation.

[9]  S. Merler,et al.  Baseline Characteristics and Outcomes of 1591 Patients Infected With SARS-CoV-2 Admitted to ICUs of the Lombardy Region, Italy. , 2020, JAMA.

[10]  Emily G McDonald,et al.  Review: Hydroxychloroquine and Chloroquine for Treatment of SARS-CoV-2 (COVID-19) , 2020, Open forum infectious diseases.

[11]  Zhan Zhang,et al.  Efficacy of hydroxychloroquine in patients with COVID-19: results of a randomized clinical trial , 2020, medRxiv.

[12]  Jason M Pogue,et al.  Coronavirus Disease 2019 Treatment: A Review of Early and Emerging Options , 2020, Open forum infectious diseases.

[13]  D. Raoult,et al.  Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial , 2020, International Journal of Antimicrobial Agents.

[14]  Yuan Wei,et al.  A Trial of Lopinavir–Ritonavir in Adults Hospitalized with Severe Covid-19 , 2020, The New England journal of medicine.

[15]  W. Applegate,et al.  COVID‐19 Presents High Risk to Older Persons , 2020, Journal of the American Geriatrics Society.

[16]  Alexis Jacquier,et al.  Clinical and microbiological effect of a combination of hydroxychloroquine and azithromycin in 80 COVID-19 patients with at least a six-day follow up: A pilot observational study , 2020, Travel Medicine and Infectious Disease.

[17]  Jianjun Gao,et al.  Breakthrough: Chloroquine phosphate has shown apparent efficacy in treatment of COVID-19 associated pneumonia in clinical studies. , 2020, Bioscience trends.

[18]  Gengfu Xiao,et al.  Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro , 2020, Cell Research.

[19]  M. Makary,et al.  Frequency and Predictors of Polypharmacy in US Medicare Patients: A Cross-Sectional Analysis at the Patient and Physician Levels , 2019, Drugs & Aging.

[20]  A. Forster,et al.  The MedSafer Study: A Controlled Trial of an Electronic Decision Support Tool for Deprescribing in Acute Care , 2019, Journal of the American Geriatrics Society.

[21]  J. Garber,et al.  Medication Overload: America's Other Drug Problem , 2019 .

[22]  J. Hanlon,et al.  American Geriatrics Society 2019 Updated AGS Beers Criteria® for Potentially Inappropriate Medication Use in Older Adults , 2019, Journal of the American Geriatrics Society.

[23]  Mario Prost.  System , 2019, Concepts for International Law.

[24]  Jung-Han Kim,et al.  Stereotactic Core-Needle Biopsy of Non-Mass Calcifications: Outcome and Accuracy at Long-Term Follow-Up , 2003, Korean journal of radiology.

[25]  Dr Rebecca Powell.  Choosing Wisely Canada recommendations. , 2018, Canadian family physician Medecin de famille canadien.

[26]  Gillian E. Caughey,et al.  What is polypharmacy? A systematic review of definitions , 2017, BMC Geriatrics.

[27]  H. Fan,et al.  Pharmacokinetics and Bioequivalence Study of Hydroxychloroquine Sulfate Tablets in Chinese Healthy Volunteers by LC–MS/MS , 2015, Rheumatology and Therapy.

[28]  Paul Gallagher,et al.  STOPP/START criteria for potentially inappropriate prescribing in older people: version 2 , 2014, Age and ageing.

[29]  Pr Depo-Provera.  PRODUCT MONOGRAPH INCLUDING PATIENT MEDICATION INFORMATION , 2015 .

[30]  Joseph Hanlon,et al.  Clinical consequences of polypharmacy in elderly , 2014, Expert opinion on drug safety.

[31]  Paul Gallagher,et al.  Potentially inappropriate medications defined by STOPP criteria and the risk of adverse drug events in older hospitalized patients. , 2011, Archives of internal medicine.

[32]  J. Baeyens,et al.  Prevalence of potentially inappropriate prescribing in an acutely ill population of older patients admitted to six European hospitals , 2011, European Journal of Clinical Pharmacology.

[33]  P. Gallagher,et al.  Inappropriate prescribing and adverse drug events in older people , 2009, BMC geriatrics.

[34]  I. McDowell,et al.  A global clinical measure of fitness and frailty in elderly people , 2005, Canadian Medical Association Journal.

[35]  G P Samsa,et al.  Adverse events after discontinuing medications in elderly outpatients. , 1997, Archives of internal medicine.

[36]  L. Brooke.  The National Library of Medicine. , 1980, Hospital libraries.